EGFR (A767_S768insTLA)
Sign in to save this workspaceEGFR · Variant type: indel · HGVS: p.A767_S768insTLA
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Mobocertinib | 100.0% | 0.0% | 97.22 |
| 2 | Neratinib | 99.1% | 0.9% | 93.18 |
| 3 | Lazertinib | 98.6% | 1.4% | 97.47 |
| 4 | Canertinib | 98.6% | 1.4% | 96.49 |
| 5 | Pralsetinib | 96.9% | 3.1% | 93.43 |
| 6 | Erlotinib | 87.1% | 12.9% | 99.75 |
| 7 | Vandetanib | 83.8% | 16.2% | 95.74 |
| 8 | Defactinib | 74.7% | 25.3% | 92.68 |
| 9 | Pacritinib | 71.6% | 28.4% | 88.64 |
| 10 | Alpelisib | 68.5% | 31.5% | 97.22 |
| 11 | Pemigatinib | 36.4% | 63.6% | 98.23 |
| 12 | Gilteritinib | 33.1% | 66.9% | 88.97 |
| 13 | Zanubrutinib | 24.3% | 75.7% | 98.24 |
| 14 | Avapritinib | 21.5% | 78.5% | 97.73 |
| 15 | Pirtobrutinib | 14.1% | 85.9% | 99.49 |
| 16 | Umbralisib | 12.7% | 87.3% | 98.74 |
| 17 | Leniolisib | 9.2% | 90.8% | 100.00 |
| 18 | Pexidartinib | 9.2% | 90.8% | 99.49 |
| 19 | Selumetinib | 6.8% | 93.2% | 100.00 |
| 20 | Rabusertib | 6.4% | 93.6% | 98.74 |
| 21 | Abrocitinib | 4.3% | 95.7% | 99.50 |
| 22 | Palbociclib | 4.3% | 95.7% | 98.75 |
| 23 | Infigratinib | 3.9% | 96.1% | 98.24 |
| 24 | Tenalisib | 3.6% | 96.4% | 97.98 |
| 25 | Mitapivat | 3.5% | 96.5% | 100.00 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Mobocertinib | 100.0% | 100.0% | +0.0% |
| Neratinib | 99.1% | 100.0% | -0.9% |
| Lazertinib | 98.6% | 100.0% | -1.4% |
| Canertinib | 98.6% | 98.4% | +0.2% |
| Pralsetinib | 96.9% | 99.1% | -2.2% |
| Erlotinib | 87.1% | 99.4% | -12.4% |
| Vandetanib | 83.8% | 99.3% | -15.5% |
| Defactinib | 74.7% | 94.6% | -19.9% |
| Pacritinib | 71.6% | — | — |
| Alpelisib | 68.5% | — | — |
| Pemigatinib | 36.4% | — | — |
| Gilteritinib | 33.1% | 91.0% | -58.0% |
| Zanubrutinib | 24.3% | 88.2% | -63.8% |
| Avapritinib | 21.5% | — | — |
| Pirtobrutinib | 14.1% | — | — |
| Umbralisib | 12.7% | — | — |
| Leniolisib | 9.2% | — | — |
| Pexidartinib | 9.2% | — | — |
| Selumetinib | 6.8% | — | — |
| Rabusertib | 6.4% | — | — |
| Abrocitinib | 4.3% | — | — |
| Palbociclib | 4.3% | — | — |
| Infigratinib | 3.9% | — | — |
| Tenalisib | 3.6% | — | — |
| Mitapivat | 3.5% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 19.3ms